Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

DORIPENEM vs DOSTARLIMAB-GXLY: Which Drug Is Safer?

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

DORIPENEM vs DOSTARLIMAB-GXLY: Safety Overview

Metric DORIPENEM DOSTARLIMAB-GXLY
Total FAERS Reports 239 504
Deaths Reported 78 55
Death Rate 32.6% 10.9%
Hospitalizations 91 126
Average Patient Age 56.2 yrs 67.4 yrs
% Female Patients 35.4% 92.7%
FDA Approval Date Oct 12, 2007 N/A
Marketing Status Discontinued Prescription